cas 386704-04-7, 6-(TRIFLUOROMETHYL)PYRIDINE-3-METHANOL

Articles about 386704-04-7Total 9 be found

Article title
Article abstract
Author
Journal number and time
Download

Sulfoxaflor hapten, preparation method thereof, antigen, antibody and application thereof
The invention provides a sulfoxaflor hapten, a method for preparing the hapten, a sulfoxaflor antigen obtained by coupling the hapten with carrier protein, a sulfoxaflor antibody obtained by immunizing animals with the sulfoxaflor antigen, and applications of the sulfoxaflor hapten, the antigen and the antibody in immunological detection. The invention further discloses a sulfoxaflor colloidal gold chromatography detection device prepared from the sulfoxaflor hapten and a method for detecting sulfoxaflor in a sample by using the sulfoxaflor colloidal gold chromatography detection device. According to the preparation method provided by the invention, used chemical reagents are easy to obtain, the operation process is simple, the reaction yield is relatively high, and the detection cost is relatively low. The detection device provided by the invention can rapidly and accurately detect the residual content of sulfoxaflor in vegetables or fruits, and can meet the requirements of supervision departments and detection organizations for on-site supervision and law enforcement. The detection method provided by the invention has the advantages of high sensitivity, strong specificity, low cost, simple operation, short detection time and long shelf life.
-
Paragraph 0120-0121

(2021/10/11)

Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia
We report herein the design and synthesis of a series of orally active, liver-targeted hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors for the treatment of anemia. In order to mitigate the concerns for potential systemic side effects, we
Liu, Ping,Wang, Liping,Dubois, Byron G.,Colandrea, Vincent J.,Liu, Rongqiang,Cai, Jiaqiang,Du, Xiaoxing,Quan, Weiguo,Morris, William,Bai, Jianwu,Bishwokarma, Bimjhana,Cheng, Mangeng,Piesvaux, Jennifer,Ray, Kallol,Alpert, Carla,Chiu, Chi-Sung,Zielstorff, Mark,Metzger, Joseph M.,Yang, Liming,Leung, Dennis,Alleyne, Candice,Vincent, Stella H.,Pucci, Vincenzo,Li, Xiaofang,Crespo, Alejandro,Stickens, Dominique,Hale, Jeffrey J.,Ujjainwalla, Feroze,Sinz, Christopher J.
supporting information
p. 1193 - 1198
(2018/12/11)

NITROGEN-CONTAINING HETEROCYCLIC ALKENYL COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL AND ORGANIC SEMICONDUCTOR DEVICE
PROBLEM TO BE SOLVED: To provide a compound that is high in charge transfer and atmosphere stability and is suitable for an organic semiconductor material, provide an organic semiconductor material comprising the compound, and provide an organic semiconductor element comprising the organic semiconductor material. SOLUTION: The present invention provides a compound represented by formula (1), specifically a compound represented by formula (2) (Ar1 is an unsaturated cyclic hydrocarbon group or the like; Ar2 is an unsaturated heterocyclic group containing nitrogen with an unshared electron pair, or the like; B is -CH=CH- or -C≡C-; X11-X13 independently represent C-R or N; at least one of X12 and X13 is N). SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2018,JPOandINPIT
-
Paragraph 0132; 0133

(2017/12/27)

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK
The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
-
Page/Page column 62; 63

(2017/04/11)

Modular Route to Azaindanes
A convergent radical based route to azaindanes is described, relying on the degenerative addition transfer of various substituted S-(pyridylmethyl)-O-ethyl dithiocarbonates (xanthates) to functional alkenes followed by radical cyclization onto the pyridine ring activated by protonation with trifluoroacetic acid. In one case, a richly decorated cyclohepta[b]pyridine could be assembled swiftly by allowing the first adduct to N-phenylmaleimide to undergo addition to N-allylphthalimide prior to cyclization.
Huang, Qi,Zard, Samir Z.
supporting information
p. 3895 - 3898
(2017/07/26)

Benzamides
The present invention is directed to benzamide containing compounds which inhibit the P2X7 receptor
-
Paragraph 0115

(2014/05/07)

NOVEL TRPV3 MODULATORS
Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Composition
-
(2013/05/21)

NOVEL TRPV3 MODULATORS
Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Composition
-
(2013/06/04)

N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR
The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitrogen; R1a is H or a straight C1-3 alkyl group; R2a is H or a methyl group R2 is selected from the group consisting of C1-3alkyl, H and -(CH2)n-, wherein n is 3 or 4 and the terminal carbon of the chain is bonded to the carbon atom adjacent to the nitrogen bearing the R2 group, such that a fused 6,5 or 6,6-bicyclic ring is formed. Y is selected from the group consisting of: phenyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, halogen, C1-3alkyl substituted by 1 to 7 fluoro atoms and C1-3alkoxy substituted by 1 to 7 fluoro atoms; pyridyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, OCH3, CF3, CN, and halogen; naphthyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of F and OCH3; pyrimidinyl; imidazo[1,2-a]pyridine-6-yl; benzothiophen-2-yl; benzothiophen-5-yl; benzofuran-2-yl; dibenzo[b,d]furan-3-yl; dibenzo[b,d]thiophen-2-yl; dibenzo[b,d]thiophen-4-yl; 1,3- benzodioxol-5-yl; 2,3-dihydro-1,4-benzodioxin-5-yl; 2,3-dihydro-1,4-benzodioxin-6-yl; 2,3- dihydro-1-benzofuran-4-yl; 2,2-difluoro-1,3-benzodiox-4-yl; pyridazinyl; imidazolyl; oxazolyl; pyrazolyl; thiazolyl; and triazolyl; with the proviso that when Y is 2,3-dihydro-1,4-benzodioxin-6-yl, R1 is not Cl; processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
-
Page/Page column 182

(2009/01/24)